alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,276–1,300 of 2,900 studies · tagged Brain Scans (page 52 of 116) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Microstructural white matter changes in cognitively normal individuals at risk of amnestic MCI

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurology 2012-07-25

Microstructural white matter changes are present in cognitively normal individuals in the pre-aMCI stage, and may serve as a potential imaging marker of early AD-related brain changes. 1 key finding →

Participants: 193 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Effect of acupuncture in mild cognitive impairment and Alzheimer disease: a functional MRI study

✓ Peer-reviewed alzhub usefulness score 50 out of 100. PloS one 2012-08-20

We aim to clarify the mechanisms of acupuncture in treating mild cognitive impairment (MCI) and Alzheimer disease (AD) by using functional magnetic resonance imaging (fMRI). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Insights into Systemic Disease through Retinal Imaging-Based Oculomics

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Translational vision science & technology 2020-02-12

Among the most noteworthy developments in ophthalmology over the last decade has been the emergence of quantifiable high-resolution imaging modalities, which are typically non-invasive, rapid and widely available. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Molecular psychiatry 2014-08-05

Cognitive impairment is highly prevalent among individuals with late-life depression (LLD) and tends to persist even after successful treatment. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Impaired Cognition and Brain Atrophy Decades After Hypertensive Pregnancy Disorders

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Circulation. Cardiovascular quality and outcomes 2016-02-01

Hypertensive pregnancy disorders are associated with worse performance on tests of processing speed and smaller brain volumes decades later. 4 key findings →

Participants: 1,279 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuropathology of White Matter Lesions, Blood-Brain Barrier Dysfunction, and Dementia

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Stroke 2017-08-30

Our data suggest that some degree of blood-brain barrier dysfunction is common in older people and that this may be related to clinical dementia risk, additional to standard MRI biomarkers. 5 key findings →

Participants: 126 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurology 2013-10-09

Patients with autopsy-confirmed low-, intermediate-, and high-likelihood DLB, according to the probability statement recommended by the third report of the DLB Consortium, and antemortem MRI, were identified (n = 75). 3 key findings →

Participants: 75 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Longitudinal trajectories of amyloid deposition, cortical thickness, and tau in Down syndrome: A deep-phenotyping case report

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2019-11-25

Until now, data on the longitudinal trajectories of amyloid accumulation, tau pathology, and brain atrophy over multiple time points remain scarce in DS. 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Magnetic resonance imaging biomarkers for the early diagnosis of Alzheimer's disease: a machine learning approach

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Frontiers in neuroscience 2015-09-01

Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor their effectiveness, as well as to lessen the time and cost of clinical trials. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of neurology, neurosurgery, and psychiatry 2000-11-01

It has been shown that atrophy of medial temporal lobe structures such as the hippocampus and entorhinal cortex shown on MRI may distinguish patients with Alzheimer's disease from healthy controls. 4 key findings →

Participants: 41 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry

✓ Peer-reviewed alzhub usefulness score 50 out of 100. NeuroImage 2008-02-21

Tensor-based morphometry (TBM) creates three-dimensional maps of disease-related differences in brain structure, based on nonlinearly registering brain MRI scans to a common image template. 4 key findings →

Participants: 120 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging

✓ Peer-reviewed alzhub usefulness score 50 out of 100. NeuroImage. Clinical 2019-03-13

Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase of Alzheimer's disease (AD), and inclusion criteria are based on biomarkers rather than clinical symptoms. 4 key findings →

Participants: 13 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cognitive correlates of ventricular enlargement and cerebral white matter lesions on magnetic resonance imaging. The Rotterdam Study

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Stroke 1994-06-01

Ventricular enlargement and white matter lesions are frequent findings on cerebral magnetic resonance imaging scans of elderly subjects. 4 key findings →

Participants: 90 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Effective feature learning and fusion of multimodality data using stage-wise deep neural network for dementia diagnosis

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Human brain mapping 2018-11-01

In this article, the authors aim to maximally utilize multimodality neuroimaging and genetic data for identifying Alzheimer's disease (AD) and its prodromal status, Mild Cognitive Impairment (MCI), from normal aging subjects. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

From across this tag

9 of the 2,885 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed